We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Genomic Health: predicting the course of an individual's can
An SI Board Since November 2006
Posts SubjectMarks Bans Symbol
38 12 0 GHDX
Emcee:  A.J. Mullen Type:  Moderated
The approach is very simple. Genomic Health have looked at the genetic structure of samples taken from tumours of patients going back 15(?) years. They know the case histories of the patients, so they are able to make statistical associations between the genetic structure and the progression of the disease. Their first test is for breast cancer.

They've developed a screen for twenty six(?) genes. A biopsy is taken from a cancerous tumor and sent to Genomic Health. They screen it against a panel of twenty six(?) genes and produce a score that estimates likelihood of recurrence. This allows the patient and doctor to make informed decisions concerning treatment.

Chemotherapy is currently recommended for more than 90% of women who have breast cancer. 83% of women who have surgery and hormone therapy alone, without chemotherapy, will not have recurrence within ten years. Chemotherapy increases that probability to 87%. For those in the 17% that would have recurrence then, chemotherapy can make a substantial difference. The problem is in deciding who's in which group. Oncotype DX (the name given to the test) helps women get the treatment appropriate for them.

The test costs $3 460, which is a lot less than either a course of chemotherapy, or the cost of treating mestastisized cancer. Medicare is reimbursing as well as Kaiser, Primera, Humana, and Aetna. They still have a way to go. They only have 30% of insurers signed up so far. I think they have only been marketing the test for a year or so.

The FDA is probably going to regulate tests of this sort. Genomic Health has validated their predictions and published the results in the New England Journal of Medicine. They welcome the regulation.

The technique can be extended to other cancers. They are working on prostate, colon, renal, and NSCLC. Together their target market is around half a million a year.

The company has a very strong management team. The CEO, Randy Scott is from Incyte, three senior managers are from Genentech, and another was with Guidant and Applied Biosystems.

More information is available at the company's website, Any discrepancy between my summary and the website is likely a result of my error.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
38I've posted the following on the Biotech Valuation Thread because I'm tiA.J. Mullen-7/28/2019
37The Best Bet in the Growing Genetic Testing Market: Genetic Health vs. Invitae fA.J. Mullen-3/7/2017
36Earnings Call: seekingalpha.comA.J. Mullen-8/3/2016
35Genomic Health Reports Continued Double-Digit Growth in Announcement of Second QA.J. Mullen-8/2/2016
34Multiple Oncotype DX® Outcomes Studies, Including Results from NCI-sponsoreA.J. Mullen-9/11/2015
33Genomic Health's Oncotype DX(R) Colon Cancer Test Predicts Individualized ReA.J. Mullen-5/15/2009
32BTW, the competition you mentioned Mammaprint (I believe) is pretty much dead. Htradeyourstocks-5/6/2008
31You make some good points Brad. I like the technology and hope it is used in guA.J. Mullen-4/26/2008
30Ashley, Thanks for starting this thread. I'm disappointed to hear that youSI Brad-4/26/2008
29Short interest has gone up significantly in the last few months WitSI Brad-4/26/2008
28I have been looking for a promising stock for several years and I've finallySI Brad-2/27/2008
27Genomic Jumps on Better-Than-Expected 4Q Wednesday February 6, 11:03 am ET Genomtnsaf-2/7/2008
26GHDX real news steveSteve Lokness-10/23/2007
25Thanks for being frank. idoidos-3/27/2007
24Having started this thread and having stated that I owned shares, I should also A.J. Mullen-3/27/2007
23AP Genomic Rises on Upgrade to 'Outperform' Tuesday March 27, 12:52 pm Eidos-3/27/2007
22Heavy buying by BAKER BROTHERS at $18.25 secform4.comidos-2/15/2007
21Thanks for that. It'll be interesting to see how it plays out. AshleyA.J. Mullen-2/8/2007
20Some competition for Oncotype DX of GHDX: nytimes.comidos-2/8/2007
19Genomic Health Announces Fourth Quarter and Year-end 2006 Financial Results and A.J. Mullen-2/7/2007
18Genomic Health shares tumbled 9% to $21.71. Analysts at Lehman Brothers cut theiidos-1/17/2007
17<Shame you missed the dip at the turn of the year. That would have been a gooidos-1/12/2007
16I bought it this time last year, just after the JP Morgan Conference. It was goA.J. Mullen-1/12/2007
15Ashley did you see this? Message 23177516 idoidos-1/12/2007
14Well done (position in GHDX)! I'll keep watching&waiting for an entry poidos-1/12/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):